FDA Approves First Gene Therapy for Rare Pediatric Immune Disorder Severe Leukocyte Adhesion Deficiency Type I

On March 26, 2026, the U.S. Food and Drug Administration approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel), the first gene therapy treatment for pediatric patients with severe Leukocyte Adhesion Deficiency Type I (LAD-I).... By: Goodwin